

Human umbilical cord blood as a future aspect for bone marrow transplantation

**An Essay
Submitted in Partial Fulfillment
of Master Degree in Clinical and
Chemical Pathology**

By

Sarah Muhammad Aqeel
M.B., B.Ch.

016.0753
S. A.



Supervisors

Prof. Hebatallah Adel Sedky
Professor of Clinical Pathology
Ain Shams University

H. Sedky

54746

Assis. Prof. Dr. Salwa Saad Mostafa Khodair
Assistant prof. of Clinical Pathology
Ain Shams University


Salwa Khodair

Dr. Lama Akram Al- Safadi
Lecturer of Clinical Pathology
Ain Shams University

Lama

Faculty of Medicine
Ain Shams University
1997





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

رَبِّنا لا تَؤاخِذْنا إِنْ نَسِينا أَوْ أَخطَأْنا
رَبِّنا ولا تَحْمِلْ عَلَيْنَا إِصْرا
كما حَمَلْتَهُ عَلَى الَّذِينَ مِنْ قَبْلِنا
رَبِّنا ولا تَحْمِلْنا ما لا طاقَةَ لَنا بِهِ
وَاعْفُ عَنّا وَارْحَمْنا
أَنْتَ مولانا فَانصُرْنا عَلَى الْقَوْمِ الْكَافِرِينَ

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

Acknowledgment

First and foremost thanks, to God.

I would like to express my gratitude to the continuous help, meticulous care and expert advice offered to me by *Professor Dr. Hebatallah Adel Sedky*, Professor of clinical pathology, Ain Shams University, in every step of this work.

And, many thanks for *Assistant professor Dr. Salwa Saad Mostafa Khodair*, Assistant professor of clinical pathology, Ain Shams University, for her kind heart, great patience and continuous support through this work.

Also, I wish to express my appreciation to *Dr. Lama Akram AC- Safadi*, lecturer of clinical pathology, Ain Shams University, for her constructive criticism and valuable comments.

Lastly, no words could even express my deepest gratitude to my ever giving family, my husband and my son. Their favor is unforgettable.

List Of Abbreviations

5-FU	:	5-FluoroUracil.
AA	:	Aplastic Anemia .
AIDS	:	Acquired Immune Deficiency Syndrome.
ALL	:	Acute Lymphocytic Leukemia.
AML	:	Acute Myeloid Leukemia.
AMM	:	Agnogeneic Myeloid Metaplasia.
BM	:	Bone Marrow.
BMT	:	Bone Marrow Transplantation.
CB	:	Cord Blood.
CBSC	:	Cord Blood Stem Cell.
CFC	:	Colony Forming Cells.
CFU-GM	:	Colony Forming Unit-Granulocyte Macrophage.
CFU-S	:	Colony Forming Unit in the Spleen.
CML	:	Chronic Myeloid Leukemia.
CMV	:	CytoMegalovirus.
CNS	:	Central Nervous System.
CY	:	Cyclophosphamide.
DMSO	:	DiMethylSulfOxide.
EPO	:	Erythropoietin.
ET	:	Essential Thrombocytosis.
FACS	:	Fluorescence Activated Cell Sorting.
G-SCF	:	Granulocyte-Colony Stimulating Factor.
GIT	:	Gastro Intestinal Tract.
GM-CSF	:	Granulocyte Macrophage-Colony Stimulating factor.
GVHD	:	Graft Versus Host Disease.
GVL	:	Graft Versus Leukemia.
HCMV	:	Human CytoMegalovirus.
HEPA	:	High Efficiency Particulated Air filters.
HGL	:	High Grade Lymphoma.

HIV	:	Human Immune deficiency Virus.
HLA	:	Human Leucocytic Antigen.
HSC	:	Hematopoietic Stem Cell.
IEF	:	Iso Electric Focusing.
IGL	:	Intermediate Grade Lymphoma.
IL	:	InterLeukin.
JCML	:	Juvenile Chronic Myeloid Leukemia.
LAK	:	Lymphokine Activated Killer cell.
LGL	:	Low Grade Lymphoma.
LTC-ICs	:	Long Term Culture Initiating Cells.
LVL	:	Large Volume Leukapheresis.
MHC	:	Major Histocompatibility Complex.
MLR	:	Mixed Lymphocyte Reaction.
MM	:	Multiple Myeloma.
MDS	:	Myelo Dysplastic Syndrome.
NK	:	Natural Killer Cell.
NMDP	:	National Marrow Donor Program.
PB	:	Peripheral Blood.
PBSCT	:	Peripheral Blood Stem Cell Transplantation.
PCR	:	Polymerase Chain Reaction.
PF	:	Programmed Freezing.
PV	:	Polycythemia Vera.
RBC	:	Red Blood Cell.
RFLP	:	Restriction Fragment Length Polymorphism.
SBA	:	Soya Bean Agglutinin.
SCF	:	Stem Cell Factor.
TBI	:	Total Body Irradiation.
Thy	:	Thymus.
TNF	:	Tumor Necrosis Factor.
UCB	:	Umbilical Cord Blood.
VOD	:	Veno Occlusive Disease.
WBC	:	White Blood Cell Count.

Table of Contents

	Subject	Page
CHAPTER 1	Introduction.	1
	Bone Marrow Transplantation.	3
	<i>Transplantation.</i>	<i>3</i>
	<i>History.</i>	<i>4</i>
	<i>Types of BMT :</i>	<i>5</i>
	Autograft.	5
	Isograft.	6
	Allograft.	6
	<i>Indications of BMT :</i>	<i>6</i>
	Hematological indications :	7
	BMT for ALL.	7
	BMT for AML.	7
	BMT for CML.	9
	BMT for Hodgkin's disease.	9
	BMT for non-Hodgkin's lymphoma.	10
	BMT for MM.	11
	BMT for MDS.	12
	BMT for AA.	12
	BMT for Thalassemia.	12
	BMT for Sickle cell disease.	13
	BMT for primary immunodeficiency disease.	14
	BMT for AIDS.	14
	Non hematological indications .	15
	<i>Donor Selection :</i>	<i>16</i>
	The major histocompatibility complex.	17
	HLA typing for class I.	18
	HLA typing for class II.	19
	<i>Complications of BMT :</i>	<i>19</i>
	Infections.	19
	Graft versus host disease.	21
	Graft failure.	28
	Veno occlusive disease of the liver.	29
	CNS complications.	31
	Endocrine disorders.	31
	Cardiovascular complications.	31
	Cataracts.	32
	Recurrence of malignant disease.	32

CHAPTER 2	Peripheral Blood Stem Cell Transplantation	34
	<i>History.</i>	<i>34</i>
	<i>Stem Cell :</i>	<i>35</i>
	Physical properties.	38
	Biological properties.	38
	Immunophenotype.	39
	<i>Indications of PBSCT.</i>	<i>41</i>
	<i>Procedures of PBSCT :</i>	<i>42</i>
	Stem cell mobilization :	42
	Chemotherapy mobilization.	42
	Hematopoietic growth factors mobilization.	43
	Combined chemotherapy and hematopoietic growth factors mobilization.	46
	Other methods for mobilization.	48
	Collection of PBSC.	49
	Cryopreservation of PBSC.	52
	PBSC infusion.	56
	<i>Allogeneic PBSCT.</i>	<i>57</i>
	<i>Applications of PBSCT :</i>	<i>60</i>
	Addition to marrow for allografting.	60
	Primary PBSCT.	62
	<i>Complications of PBSCT :</i>	<i>63</i>
	Complications attributable to stem cell mobilization and harvesting.	63
	Complications attributable to the infusion of cryopreserved stem cells.	66
	<i>PBSC Versus BMT :</i>	<i>67</i>
	Hematopoietic engraftment.	67
	Tumor cell contamination and antitumor effect.	69
	Other advantages.	71
CHAPTER 3	Umbilical Cord Blood Transplantation.	73
	<i>Clinical Applications.</i>	<i>75</i>
	<i>Future Directions of Cord Blood.</i>	<i>75</i>
	<i>Collection of Umbilical Cord Blood.</i>	<i>76</i>

	<i>Immunologic perspectives of UCB cells :</i>	79
	phenotypic, proliferative and self-renewal characteristics of stem and progenitor cells in CB.	82
	GVHD Potential and The Possible Presence of Maternal Lymphocytes in Placental Blood.	86
	Transplacentally Passaged Maternal Anti-HLA Antibodies.	88
	<i>Number of Stem Cells in Placental Blood</i>	89
	<i>Infectious Disease Considerations.</i>	91
	<i>Potential Advantages.</i>	93
	<i>Ethical Quandary.</i>	95
	<i>Cord Blood Banking.</i>	96
	<i>Conclusion.</i>	100
	Summary.	103
	References.	107

